Post by Uncle on Oct 10, 2015 1:23:25 GMT
The latest MotleyFool article came out today By Sean Williams titled, "Seasoned Biotech Investors Should Consider Diving More Deeply into Opko Health.", once again mentioning that analysts are questioning Rayaldee on whether it’ll even make it to $500 million in peak annual sales.
So is someone or somebody actually questioning Rayaldee’s upside, or are these 'Analysts' that everyone is talking about resemble Harvey the six-foot rabbit.
October 22, 2013
MotleyFool
Rayaldee is Opko's brightest hope, since current methods of treating vitamin D deficiency in patients with kidney disease can cause severe side effects, such as the accumulation of calcium, which further damages the kidneys. Rayaldee was designed to avoid these side effects. Prolor Biotech President Shai Novik stated that if Rayaldee can capture just half of the market, it could achieve annual peak sales of $6 billion.
September 24, 2015
MotleyFool
Rayaldee helps prevent and treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The FDA accepted Opko's New Drug Application for Rayaldee in July. Over 20 million Americans have stage 3 or higher CKD -- and there's no approved treatment. Analysts think Rayaldee could hit peak annual sales of more than $500 million, assuming it wins regulatory approval.
September 28, 2015
Benzinga
Other factors that have impacted the company’s shares include concerns surrounding the “the future of the company’s 4Kscore test for prostate disease, a perceived delay in the commercialization timetable of the company’s long-lasting human growth hormone products (adult and pediatric indications), and questions about Rayaldee’s upside,” Petusky added.
October 9, 2015
MotleyFool
For starters, Wall Street and investors aren’t certain that Rayaldee will sell particularly well as a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin Dinsufficiency. Once believed to have blockbuster peak sales potential, some analysts question whether it’ll even make it to $500 million in peak annual sales.
Analyst Firms Making Recommendations
Barrington Research’s - Michael Petusky
March 26, 2015
"We are assuming coverage of OPKO Health due to an analyst transition. Headquartered in Miami, Florida OPKO primarily focuses on point-of-care diagnostics, novel molecular diagnostics, and pharmaceuticals...Led by long-time healthcare executive Phillip Frost, OPKO has many additional shots on goal even beyond the opportunities within its currently commercialized product portfolio and its front-burner pipeline products, Rayaldee, and hGH-CTP. We have included information on pages 2 and 3, which illustrates key aspects of the current product portfolio as well as the depth of the product pipeline."
September 29, 2015
Petusky has maintained an Outperform rating for the stock; however he’s reduced his price target slightly to $19, from $20. As per the analyst, the reasons behind the declining stock price are certain company-
specific issues and a general weakness in the pharmaceutical space. Investors were apprehensive about the company’s recently concluded acquisition of Bio-Reference Laboratories, a full-service clinical diagnostic laboratory. The analyst is optimistic about the acquisition, as he believes it has provided Opko with profitable revenue of $1 billion. Additionally, the acquisition has also transformed Opko from a development stage company into one with meaningful operations. However, he stated that the company needs to explain the rationale behind this acquisition. Some of the other factors behind the drop include, “the future of the company’s 4Kscore test for prostate disease, a perceived delay in the commercialization timetable of the company’s long-lasting human growth hormone products (adult and pediatric indications), and questions about Rayaldee’s upside.” In July, the company had sought approval from the FDA for Rayaldee, an oral vitamin D prohormone treatment being developed for SHPT in patients with stage 3 or 4 CKD and vitamin D insufficiency. Petusky is also positive about the 4K Score test, which if successful will make biopsies redundant. He also believes the 4K Score test offers significant commercial potential and can boost Opko’s performance.
Barrington - Tareq Affouri
September 28, 2015
OPKO Health long-term thesis intact despite selloff, says Barrington. Barrington analyst Tareq Affouri says the long-term thesis for OPKO Health remains intact despite the 55% pullback in shares from the June high. He lowered his price target for the stock to $19 from $20 and keeps an Outperform rating on the name.
Jefferies - Brandon Couillard
September 11, 2015
Couillard noted, “OPK is emerging as a diversified hybrid medical products company focused on novel diagnostics (Dx) & drugs. The acquisition of BRLI adds a compelling distribution channel & commercial team for OPK’s unique blood-based prostate cancer risk test (4Kscore) & future new point-of-care launches, but timing of reimbursement milestones is unclear. With diagnostics accounting for >70% of revs thru 2020E, we are assuming coverage at Hold/$11 PT.”
Ladenburg - Kevin DeGeeter
May 6, 2014
“OPKO Health Inc. reiterated plans to complete its follow-up of the second Phase 3 efficacy study of Rayaldee in July and present its results in Q3/14. . .the release of the top-line efficacy data will be a material catalyst for the company’s shares and a potentially transformational milestone for expansion of its renal products division. Our forecast calls for Rayaldee to achieve peak sales of $600M+ in the treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.”
September 2, 2015
Ladenburg Thalmann analyst Kevin Degeeter reiterated a Buy rating on OPK, with a price target of $20
Laidlaw & Co - Jim Molloy
Laidlaw & Co -Yale Jen
Aug 12, 2015
“The recent Bio-Reference Laboratories acquisition brings additional revenue plus a large sales force to support OPKs 4Kscore test sales. Coupled with three drugs in OPK’s pipeline that potentially could be approved and enter the market over the next 24 months; the company is in a transformative stage in our opinion. We estimate OPK could become cash positive starting 2016 with continued margin improvements going forward as product mix improves.”
Oppenheimer & Co. - Rohit Vanjani
March 3, 2015
Shares of OPKO ended flattish after reporting a top-line beat, largely on a milestone payment from partner Tesaro. The 4Kscore test continues to ramp with management still highlighting end 2015 as a potential inflection point in sales, when the test is expected to start getting reimbursed. The company has a number of catalysts in 2015 including the NDA filing for Rayaldee in 1Q15, start of a phase 2 Factor VII trial in 1H15, the Rolapitant PDUFA in September 2015, and initiation of the Alpharen phase 3 trial in 2H15. Despite these catalysts, we downgrade OPKO to Perform and remove our $12 price target.
STOP THE PRESS
This befuddle Uncle for awhile. DD always wins in the end. Here it is......
Aug 6, 2015 at 5:30PM
"On the other hand, Opko has a bounty of catalysts within arm's reach that could provide an almost immediate boost to its bottom-line and stock price. The Food and Drug Administration's PDUFA decision date on rolapitant for chemotherapy-induced nausea and vomiting is less than a month away – rolapitant could deliver peak annual sales of $300 million to $500 million – and before the end of March 2016 we should have an answer from the FDA on rayaldee as a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease. Rayaldee could generate north of a half-billion in peak annual sales. Coupled with its acquisitions, Opko's revenue growth could accelerate quickly."
So who is this Great Analyst?
J.P. Morgan, Cowen & Co., Deutsche Bank, Credit Suisse, Merrill Lynch, Morgan Stanley, Barclays or Goldman Sachs?
NO...The Winner Is:
Sean Williams of Motley Fool reported this on Agust 6, 2015 in a piece titled, 'Opko Health Shares Were Slammed -- Here's Why.'
Who is Sean Williams and what Analyst Firm does is work for?
Sean Williams is a Motley Fool Contributor.
What are the qualifications to become a Fool Contributor?
None, just agree to their Terms Click Here
"While anyone who agrees to the Fool’s Rules can post, there are some additional terms and conditions (the “Terms”) you need to be aware of if you want to be a compensated contributor."
Sean Williams Qualifications
A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.
On another note.
On Jun 28, 2015 at 11:03AM Todd Campbell another Fool Contributor came out with an article titled, 'The Biotech Drug Lord: How One Man Is Conquering The Biotech Space.'
He stated that: "He also picked up a company called Cytochroma for Opko Health that landed him a drug named Rayaldee." "Rayaldee is a vitamin D hormone that's used in chronic kidney-disease patients -- a very underserved market -- and that could be worth $3 billion on the market a year, or more."
Todd Campbell Qualifications
Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.
Uncle's Note
So it would appear we have a disagreement here Amongst Fools on two separate occasions.
I guess it's wise to take heed to the old Proverb "Fool me once, shame on you; fool me twice, shame on me."
Or was that Former President Bush that had it correct: 'Fool me once, shame on ... shame on you. Fool me... You can't get fooled again!'"
If I’m wrong on this, would someone please post any DD from the reputable analyst that questioned Rayaldee on whether it’ll even make it to $500 million in peak annual sales. The only reference close to that projection was from Ladenburg - Kevin DeGeeter from May of 2014, dated material.
So is someone or somebody actually questioning Rayaldee’s upside, or are these 'Analysts' that everyone is talking about resemble Harvey the six-foot rabbit.
October 22, 2013
MotleyFool
Rayaldee is Opko's brightest hope, since current methods of treating vitamin D deficiency in patients with kidney disease can cause severe side effects, such as the accumulation of calcium, which further damages the kidneys. Rayaldee was designed to avoid these side effects. Prolor Biotech President Shai Novik stated that if Rayaldee can capture just half of the market, it could achieve annual peak sales of $6 billion.
September 24, 2015
MotleyFool
Rayaldee helps prevent and treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The FDA accepted Opko's New Drug Application for Rayaldee in July. Over 20 million Americans have stage 3 or higher CKD -- and there's no approved treatment. Analysts think Rayaldee could hit peak annual sales of more than $500 million, assuming it wins regulatory approval.
September 28, 2015
Benzinga
Other factors that have impacted the company’s shares include concerns surrounding the “the future of the company’s 4Kscore test for prostate disease, a perceived delay in the commercialization timetable of the company’s long-lasting human growth hormone products (adult and pediatric indications), and questions about Rayaldee’s upside,” Petusky added.
October 9, 2015
MotleyFool
For starters, Wall Street and investors aren’t certain that Rayaldee will sell particularly well as a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin Dinsufficiency. Once believed to have blockbuster peak sales potential, some analysts question whether it’ll even make it to $500 million in peak annual sales.
Analyst Firms Making Recommendations
Barrington Research’s - Michael Petusky
March 26, 2015
"We are assuming coverage of OPKO Health due to an analyst transition. Headquartered in Miami, Florida OPKO primarily focuses on point-of-care diagnostics, novel molecular diagnostics, and pharmaceuticals...Led by long-time healthcare executive Phillip Frost, OPKO has many additional shots on goal even beyond the opportunities within its currently commercialized product portfolio and its front-burner pipeline products, Rayaldee, and hGH-CTP. We have included information on pages 2 and 3, which illustrates key aspects of the current product portfolio as well as the depth of the product pipeline."
September 29, 2015
Petusky has maintained an Outperform rating for the stock; however he’s reduced his price target slightly to $19, from $20. As per the analyst, the reasons behind the declining stock price are certain company-
specific issues and a general weakness in the pharmaceutical space. Investors were apprehensive about the company’s recently concluded acquisition of Bio-Reference Laboratories, a full-service clinical diagnostic laboratory. The analyst is optimistic about the acquisition, as he believes it has provided Opko with profitable revenue of $1 billion. Additionally, the acquisition has also transformed Opko from a development stage company into one with meaningful operations. However, he stated that the company needs to explain the rationale behind this acquisition. Some of the other factors behind the drop include, “the future of the company’s 4Kscore test for prostate disease, a perceived delay in the commercialization timetable of the company’s long-lasting human growth hormone products (adult and pediatric indications), and questions about Rayaldee’s upside.” In July, the company had sought approval from the FDA for Rayaldee, an oral vitamin D prohormone treatment being developed for SHPT in patients with stage 3 or 4 CKD and vitamin D insufficiency. Petusky is also positive about the 4K Score test, which if successful will make biopsies redundant. He also believes the 4K Score test offers significant commercial potential and can boost Opko’s performance.
Barrington - Tareq Affouri
September 28, 2015
OPKO Health long-term thesis intact despite selloff, says Barrington. Barrington analyst Tareq Affouri says the long-term thesis for OPKO Health remains intact despite the 55% pullback in shares from the June high. He lowered his price target for the stock to $19 from $20 and keeps an Outperform rating on the name.
Jefferies - Brandon Couillard
September 11, 2015
Couillard noted, “OPK is emerging as a diversified hybrid medical products company focused on novel diagnostics (Dx) & drugs. The acquisition of BRLI adds a compelling distribution channel & commercial team for OPK’s unique blood-based prostate cancer risk test (4Kscore) & future new point-of-care launches, but timing of reimbursement milestones is unclear. With diagnostics accounting for >70% of revs thru 2020E, we are assuming coverage at Hold/$11 PT.”
Ladenburg - Kevin DeGeeter
May 6, 2014
“OPKO Health Inc. reiterated plans to complete its follow-up of the second Phase 3 efficacy study of Rayaldee in July and present its results in Q3/14. . .the release of the top-line efficacy data will be a material catalyst for the company’s shares and a potentially transformational milestone for expansion of its renal products division. Our forecast calls for Rayaldee to achieve peak sales of $600M+ in the treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.”
September 2, 2015
Ladenburg Thalmann analyst Kevin Degeeter reiterated a Buy rating on OPK, with a price target of $20
Laidlaw & Co - Jim Molloy
Laidlaw & Co -Yale Jen
Aug 12, 2015
“The recent Bio-Reference Laboratories acquisition brings additional revenue plus a large sales force to support OPKs 4Kscore test sales. Coupled with three drugs in OPK’s pipeline that potentially could be approved and enter the market over the next 24 months; the company is in a transformative stage in our opinion. We estimate OPK could become cash positive starting 2016 with continued margin improvements going forward as product mix improves.”
Oppenheimer & Co. - Rohit Vanjani
March 3, 2015
Shares of OPKO ended flattish after reporting a top-line beat, largely on a milestone payment from partner Tesaro. The 4Kscore test continues to ramp with management still highlighting end 2015 as a potential inflection point in sales, when the test is expected to start getting reimbursed. The company has a number of catalysts in 2015 including the NDA filing for Rayaldee in 1Q15, start of a phase 2 Factor VII trial in 1H15, the Rolapitant PDUFA in September 2015, and initiation of the Alpharen phase 3 trial in 2H15. Despite these catalysts, we downgrade OPKO to Perform and remove our $12 price target.
STOP THE PRESS
This befuddle Uncle for awhile. DD always wins in the end. Here it is......
Aug 6, 2015 at 5:30PM
"On the other hand, Opko has a bounty of catalysts within arm's reach that could provide an almost immediate boost to its bottom-line and stock price. The Food and Drug Administration's PDUFA decision date on rolapitant for chemotherapy-induced nausea and vomiting is less than a month away – rolapitant could deliver peak annual sales of $300 million to $500 million – and before the end of March 2016 we should have an answer from the FDA on rayaldee as a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease. Rayaldee could generate north of a half-billion in peak annual sales. Coupled with its acquisitions, Opko's revenue growth could accelerate quickly."
So who is this Great Analyst?
J.P. Morgan, Cowen & Co., Deutsche Bank, Credit Suisse, Merrill Lynch, Morgan Stanley, Barclays or Goldman Sachs?
NO...The Winner Is:
Sean Williams of Motley Fool reported this on Agust 6, 2015 in a piece titled, 'Opko Health Shares Were Slammed -- Here's Why.'
Who is Sean Williams and what Analyst Firm does is work for?
Sean Williams is a Motley Fool Contributor.
What are the qualifications to become a Fool Contributor?
None, just agree to their Terms Click Here
"While anyone who agrees to the Fool’s Rules can post, there are some additional terms and conditions (the “Terms”) you need to be aware of if you want to be a compensated contributor."
Sean Williams Qualifications
A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.
On another note.
On Jun 28, 2015 at 11:03AM Todd Campbell another Fool Contributor came out with an article titled, 'The Biotech Drug Lord: How One Man Is Conquering The Biotech Space.'
He stated that: "He also picked up a company called Cytochroma for Opko Health that landed him a drug named Rayaldee." "Rayaldee is a vitamin D hormone that's used in chronic kidney-disease patients -- a very underserved market -- and that could be worth $3 billion on the market a year, or more."
Todd Campbell Qualifications
Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.
Uncle's Note
So it would appear we have a disagreement here Amongst Fools on two separate occasions.
I guess it's wise to take heed to the old Proverb "Fool me once, shame on you; fool me twice, shame on me."
Or was that Former President Bush that had it correct: 'Fool me once, shame on ... shame on you. Fool me... You can't get fooled again!'"
If I’m wrong on this, would someone please post any DD from the reputable analyst that questioned Rayaldee on whether it’ll even make it to $500 million in peak annual sales. The only reference close to that projection was from Ladenburg - Kevin DeGeeter from May of 2014, dated material.
